AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01972776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT01757587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg 2 tablets / day on 3 months, both periods of treatment
Trial: NCT00501462
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 250 mg dose of drug
Trial: NCT00537680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
Trial: NCT00179517
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02858804
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m2, IV, d1-4
Trial: NCT02858804
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 ,d5
Trial: NCT04398004
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with 500 mg Clarithromycin orally twice daily for seven days
Trial: NCT01555749
Drug: NNC172-2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
Trial: NCT01555749
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection administered subcutaneously (s.c., under the skin)
Trial: NCT02630251
Drug: GSK2820151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
Trial: NCT02731430
Drug: intrathecal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
Trial: NCT04000139
Drug: Standardized anthocyanin-rich extract
RxNorm normalized name: Vitis vinifera anthocyanins extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
Trial: NCT04000139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
Trial: NCT02174627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
Trial: NCT03481972
Drug: Doxycycline and tauroursodeoxycholic acid
RxNorm normalized name: Tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycicline and tauroursodeoxycholic acid
Trial: NCT03858972
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reduced dose of capecitabine
Trial: NCT02935712
Drug: AZD8601+Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
Trial: NCT02935712
Drug: Placebo+Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are randomized to receive 2 placebo treatments.
Trial: NCT01938638
Drug: BAY1143572
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01537042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period.
Trial: NCT02473627
Drug: DS-1971a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg tablet
Trial: NCT02473627
Drug: Buproprion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg Prolonged release tablet
Trial: NCT00413582
Drug: Patient-Controlled IV Analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are \> 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of \> 4/10 throughout the duration of PCA use.
Trial: NCT00019773
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01804946
Drug: Ergoferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and Efficiency of Ergoferon in treatment of Influenza
Trial: NCT00315458
Drug: Placebo transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match buprenorphine transdermal patch 10 or 20.
Trial: NCT02433184
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
Trial: NCT02433184
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
Trial: NCT00147875
Drug: Doxorubicin (Adriamycin)
RxNorm normalized name: doxorubicin Injection [Adriamycin]
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00722137
Drug: Cyclophosphamide 750 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Trial: NCT00722137
Drug: Doxorubicin 50 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
Trial: NCT00722137
Drug: VELCADE 1.3 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
Trial: NCT02822937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT00333827
Drug: optimal therapy for cardiaca failure
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimal therapy for cardiaca failure
Trial: NCT01006304
Drug: JNJ-39439335, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02913118
Drug: Fluoroquinolones
RxNorm normalized name: Fluoroquinolones
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02913118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02553018
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00733421
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg once daily
Trial: NCT04344483
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
Trial: NCT00075205
Drug: SR141716 (Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04239755
Drug: Doxycycline 100 MG Oral Tablet
RxNorm normalized name: DOXYCYCLINE 100 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
Trial: NCT01441024
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg per day of DAS181-FO3 for 5 days
Trial: NCT00191581
Drug: Human Insulin Mix 50:50
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01217112
Drug: GWP42003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg capsules, PO, BD, 91 days
Trial: NCT01217112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg capsules, QDS, PO, 91 days
Trial: NCT02596971
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Trial: NCT02596971
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered at a dose of 50 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Trial: NCT04671420
Drug: Mabthera®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
Trial: NCT03588910
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
Trial: NCT03588910
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
Trial: NCT00536939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, daily, until disease progression
Trial: NCT03096314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
Trial: NCT02235064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing cellulose powder of same color as experimental arm
Trial: NCT00516022
Drug: Mistletoe extract
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be administered 3 times a week at home.
Trial: NCT03532425
Drug: B/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet taken orally once daily
Trial: NCT01174823
Drug: placebo comparator ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT01692041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml per os twice daily
Trial: NCT02764762
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate oral tablets.
Trial: NCT02194283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03548961
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
Trial: NCT02962583
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02962583
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02811510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill (no active cannabinoids)
Trial: NCT02806908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04404543
Drug: SYHA1807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation Cohort Administration: Orally
Trial: NCT04404543
Drug: SYHA1807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Expansion Cohort Administration: Orally
Trial: NCT00946972
Drug: JNJ-38431055; Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281448
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281448
Drug: Contraceptives, Oral, Combined
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01071642
Drug: stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
Trial: NCT01071642
Drug: ACE/ARB stopped 24 hours before procedure and start immediately after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
Trial: NCT04283240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02930772
Drug: BAY987516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z46-100)
Trial: NCT02805153
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00791778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
Trial: NCT01082328
Drug: Kuvan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
Trial: NCT00172198
Drug: Omegaven 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00957801
Drug: Testosterone injection
RxNorm normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg single IM injection
Trial: NCT00957801
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 10 mg. administered topically daily for seven days
Trial: NCT00031590
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
Trial: NCT03956979
Drug: JM-010 group B
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JM-010 fixed combination drug (Group B) + Placebo 1
Trial: NCT03956979
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 + Placebo 2
Trial: NCT00683722
Drug: Prochymal™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of ex- vivo cultured adult human mesenchymal stem cells.
Trial: NCT00683722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of excipient of Prochymal™.
Trial: NCT00448266
Drug: dose dense adriamycine and cyclophosphamide
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose dense adriamycine and cyclophosphamide, Q 2 weeks
Trial: NCT02124655
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01283464
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.02% cream
Trial: NCT01282684
Drug: PLX5622
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
Trial: NCT01282684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for PLX5622.
Trial: NCT02224651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
Trial: NCT02224651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
Trial: NCT04746287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00772590
Drug: Hyper-immune Bovine Colostrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 1800mg, twice daily
Trial: NCT04103892
Drug: CLE-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of CLE-100 administered once daily
Trial: NCT04103892
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of placebo administered once daily
Trial: NCT02450201
Drug: Pyruvate
RxNorm normalized name: Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01498796
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01498796
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00722358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo
Trial: NCT03629262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Trial: NCT00655993
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg po daily
Trial: NCT00929370
Drug: Glycine Transporter-1 inhibitor
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
Trial: NCT03337087
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03337087
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04505657
Drug: celecoxib plus lidocaine
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Trial: NCT04505657
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
Trial: NCT00663416
Drug: NTx™-265: rhCG, then rEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
Trial: NCT02992041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0 mg of VVZ-149
Trial: NCT01514981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo on study day 1.
Trial: NCT02859337
Drug: UPA-ECx1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
Trial: NCT02859337
Drug: UPA-ECx2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
Trial: NCT03077477
Drug: AMXT 1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
Trial: NCT03077477
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered
Trial: NCT01486446
Drug: XPF-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
Trial: NCT01486446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.